Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL1234791 | 0.98 | MGAM (0.44) | NAAADGKAMGAMGAASI | |
| Hexane SCHEMBL9545643 | 0.92 | MGAM (0.40) | NAAADGKAMGAMGAASI | |
| Hexane SCHEMBL8222570 | 0.91 | MGAM (0.39) | NAAADGKAMGAMGAASI | |
| SCHEMBL8677 | 0.89 | — | — | |
| Methyl Alcohol SCHEMBL275175 | 0.87 | GAA (0.50) | MGAMGAASIMGAM2LMNA | |
| Ammonia Solution, Strong SCHEMBL3775021 | 0.87 | GAA (0.50) | MGAMGAASIMGAM2LMNA | |
| SCHEMBL7319778 | 0.86 | NAAA (0.62) | NAAADGKAMAPTLMNAL3MBTL1 | |
| Alcohol SCHEMBL4242917 | 0.85 | GAA (0.48) | MGAMGAASIMGAM2LMNA | |
| Acetone SCHEMBL7006638 | 0.85 | GAA (0.48) | MGAMGAASIMGAM2LMNA | |
| Methylene Chloride SCHEMBL3731960 | 0.85 | GAA (0.48) | MGAMGAASIMGAM2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420646-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PAH P&U LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | PHARMACIA & UPJOHN COMPANY | 2011-04-21 | — | — | US | disclosed |
| EP-1551849-B1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100022524-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7605157-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1896444-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF PROTECTED -(+)-CATECHIN AND (-)-EPICATECHIN NOMOMERS, FOR COUPLING THE PROTECTED MONOMERS WITH AN ACTIVATED, PROTECTED EPICATECHIN MONOMER, AND FOR THE PREPARATION OF EPICATECHIN-(4 , 8)-EPICATECHIN OR -CATECHIN DIMERS AND THEIR DIGALLATES | MARS, INCORPORATED (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070161630-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2007-07-12 | — | — | US | disclosed |
| US-7208490-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2007005248-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF PROTECTED -(+)-CATECHIN AND (-)-EPICATECHIN NOMOMERS, FOR COUPLING THE PROTECTED MONOMERS WITH AN ACTIVATED, PROTECTED EPICATECHIN MONOMER, AND FOR THE PREPARATION OF EPICATECHIN-(4β, 8)-EPICATECHIN OR -CATECHIN DIMERS AND THEIR DIGALLATES | MARS, INCORPORATED (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004796-A1 | Processes for the preparation of protected-(+)-catechin and (-)-epicatechin monomers, for coupling the protected monomers with an activated, protected epicatechin monomer, and for the preparation of epicatechin-(4B,8)-epicatechin or -catechin dimers and their digallates | MARS, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1551849-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2004-08-19 | — | — | US | disclosed |
| WO-2004031195-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-04-15 | — | — | WO | disclosed |
| EP-1113329-A1 | Photographic element, compound, and process | EASTMAN KODAK COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6207363-B1 | CYAN ?NB COUPLER? | EASTMAN KODAK COMPANY | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | QTRT1, QTRT2, NQO2 | NAAA 795/4885DGKA 4172/4885MGAM 2345/4885 |
| US-20070161630-A1 | Tricyclic tetrahydroquinoline antibacterial agents | QTRT1, QTRT2, NQO2 | NAAA 795/4885DGKA 4172/4885MGAM 2345/4885 |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | QTRT1, QTRT2, NQO2 | NAAA 795/4885DGKA 4172/4885MGAM 2345/4885 |
| US-20100022524-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | QTRT1, QTRT2, NQO2 | NAAA 795/4885DGKA 4172/4885MGAM 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.